Novo Nordisk Pharmatech returns to CPhI North America with latest cGMP quats

Bagsvaerd, Denmark: – Leading Danish biopharma manufacturer and diabetes specialist, Novo Nordisk Pharmatech, is returning to the new CPhI North America event in Philadelphia to showcase its expanded range of FeF™ branded Quats, manufactured in accordance with cGMP Guide ICH Q7 for Active Pharmaceutical Ingredients, the highest available standard using an innovative synthesis process.

The Danish-based specialist was present at last year’s inaugural CPhI north America event and once again will be exhibiting alongside its US distributor Brenntag Specialties, this time at Booth 927 at the Pennsylvania Convention Center.

FeF™ Quats range

The Novo Nordisk Pharmatech display will highlight the company’s cGMP Quats range, particularly Benzalkonium chloride, Cetrimide, CTAB and Strong Cetrimide Solution.

The Novo Nordisk Pharmatech team will be headed by Product Manager Chantale Julien, and Technical Sales Manager Henrik Ammitzbøll Petersen.

Secure global supply

“We found the initial CPhI north America to be great platform for reaching out to our core user base of purchasing, QA and pharma formulations decision makers,” commented Chantale Julien.

“These are people looking for global regulatory compliance with documentation, consistent high quality and continuous availability backed by a secure global supply chain and high levels of service and support. In all those criteria, Novo Nordisk Pharmatech can deliver,” said Ms. Julien.

High purity levels

The Novo Nordisk Pharmatech products on show exhibit high purity levels that make them ideal as preservatives or active ingredients in many ophthalmic, nasal, oral and topical drugs and in a variety of solutions, ointments and creams. They can also be used as lysing or precipitating agents in vaccine production.

About Novo Nordisk Pharmatech

Novo Nordisk Pharmatech A/S was established in 1949 as FeF Chemicals, and now part of the Novo Nordisk pharmaceutical group since its acquisition in 1986. On September 1, 2015, the company became Novo Nordisk Pharmatech A/S. It is the leading worldwide supplier of recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (Quats) for the pharmaceutical, biopharmaceutical and personal care industries.

The company markets its diabetic care, hemophilia, growth hormone therapy, obesity, and hormone replacement therapy (HRT) products worldwide, with customers in more than 180 countries.

All Novo Nordisk Pharmatech products are manufactured to cGMP standards. The company has distinguished itself for global regulatory compliance, consistent high quality, extensive regulatory documentation, continuous availability, security of its global supply chain and high levels of service and support.

For Financial Year 2016, Novo Nordisk Pharmatech reported world sales totaling 669 million Danish kroner (DEK) with more than half of all sales recorded in North America.

About CPhI North America

CPhI North America made its debut in 2017 as a new development of the highly successful CPhI worldwide franchise first established in 1989. Originally conceived as a chemical and pharmaceutical ingredients show, CPhI is now a global series of events for the whole pharmaceutical value chain, taking in events all over the world attracting more than 100,000 attendees annually.

The second CPhI North America Expo is a three-day event opening April 24, 2018, once again at the Pennsylvania Convention Center in Philadelphia. It is branded as seven shows in one, co-locating CPhI Connect for pharmaceutical ingredients with six other zones, including Informex (fine and specialty chemicals), iCSE (drugs development) FDF (finished drug products), P-Mec (Machinery), and InnoPack for packaging.

The conference is powered by three tracks of programming covering Drug Development, Drug Manufacturing and Bio-Processing.

CPhI North America is staged by leading Global B2B events organizer and publisher UBM Live, with more information at: http://cphinorthamerica.com.